Mind Medicine (MindMed) Inc. Subordinate Stock News

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to

As the main stock indices like the S&P 500 and Nasdaq continue to climb, penny stocks are becoming attractive for those seeking significant returns. Despite their reputation for extreme price fluctuat

Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.

Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to

Imagine you could go back in time to find last decade's long-term stocks to buy. Nvidia (NASDAQ: NVDA ) returned nearly 20,000% growth since 2014.

Regulatory risk in the psychedelic industry is decreasing, which is a positive sign for investors. Institutional investors are becoming more willing to invest in leading psychedelic companies through

The stock market continues to question whether a large cap dominance — especially that from The Magnificent Seven — is indeed the best way to invest. While investing in large cap firms is undoubte

Biotech breakthrough stocks, along with the sector overall, faced significant challenges over the past two years, with venture capital drying up, shifts in the post-pandemic healthcare landscape and t

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to

Higher interest rates, pricier debt and an overemphasis on mega-caps over the past year mean that top small-cap stocks have played second fiddle to big-name giants like Nvidia (NASDAQ: NVDA ). But tid

NEW YORK--(BUSINESS WIRE)---- $MNMD--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates t

Mind Medicine has an exciting treatment option for generalized anxiety disorder -- MM120. In clinical trials, MM120 reduced anxiety in patients after just a single dose.

MindMed's (MNMD) progress with the development of its lead candidate MM120 for treating generalized anxiety disorder has been encouraging, leading the stock to rise during this time.